Iron Deficiency Diagnosis and Treatment

Diagnostic Indicators

• Low ferritin is the most specific indicator of depleted iron stores, according to the Centers for Disease Control and Prevention (CDC) 1
• A transferrin saturation less than 16% is the standard threshold indicating iron deficiency in adults, as recommended by the CDC 1
• Transferrin saturation below 20% is suggestive of iron deficiency and warrants clinical consideration, according to the National Kidney Foundation 2, 3
• Ferritin levels below 30 μg/L indicate depleted iron stores, and levels below 15 μg/L are highly specific for iron deficiency (specificity 0.99), according to the British Society of Gastroenterology 4
• The following table shows the interpretation of transferrin saturation:

1, 2

• Mean Corpuscular Volume (MCV) is decreased, with iron deficiency typically causing microcytic anemia (MCV < 80 fL) 5
• Essential tests for diagnosing iron deficiency include complete iron studies, including serum ferritin, transferrin saturation, and complete blood count with MCV, as recommended by the American Journal of Hematology 6, 7

Treatment Guidelines

• The American Gastroenterological Association recommends oral iron supplementation as first-line therapy for iron deficiency anemia, with intravenous iron reserved for patients with specific indications such as intolerance to oral iron, poor response, or conditions that impair absorption 8
• The recommended dosing for ferrous sulfate is 65 mg elemental iron once daily, with morning administration being optimal due to circadian hepcidin patterns, and treatment should continue for 3 months after hemoglobin normalization to replenish iron stores 8, 9
• The following table outlines the recommended intravenous iron dosage based on weight and hemoglobin:

10

• Intravenous iron is indicated for patients with intolerance to oral iron, inadequate response to oral iron, hemoglobin below 10 g/dL, active inflammatory bowel disease, chronic kidney disease, malabsorption syndromes, or need for rapid iron repletion 8, 10
• In patients with inflammatory bowel disease, intravenous iron is indicated for moderate-severe anemia (Hb <10 g/dL) or with active inflammation 8, 10
• In patients with chronic kidney disease, intravenous iron should be considered if oral iron is ineffective or poorly tolerated 10
• In heart failure, consider IV iron for TSAT <20% and ferritin <100 μg/L or <300 μg/L with TSAT <20%, according to Gut 4

Monitoring and Follow-up

• Iron studies (ferritin, transferrin saturation, CBC) should be repeated 4-8 weeks after initiating treatment, with a target increase in hemoglobin of at least 2 g/dL within 4 weeks 8
• Repeat iron studies (ferritin, transferrin saturation, CBC) should be performed 4-8 weeks after initiating treatment to monitor response to therapy, and patients with chronic kidney disease should be monitored closely, as transferrin is less reliable as a nutritional marker due to effects of iron therapy, blood loss from hemodialysis, and erythropoietin therapy, as noted by the American Journal of Kidney Diseases 6, 11
• Iron parameters should not be checked within 4 weeks of IV iron administration as circulating iron interferes with the assay, and monitoring every 3 months during active treatment is recommended, with a target increase in hemoglobin of at least 2 g/dL within 4 weeks of treatment, as recommended by the American Journal of Hematology 6, 10, 12

Special Considerations

• Patients with functional iron deficiency, characterized by low iron saturation and elevated ferritin, should receive oral iron supplementation as first-line therapy, with consideration for intravenous iron if there is inadequate response, as seen in anemia of chronic disease or anemia of inflammation, according to the Kidney International guidelines 13
• Hereditary hemochromatosis is characterized by elevated serum iron levels, low Total Iron Binding Capacity (TIBC), high transferrin saturation (>45% in females, >50% in males), and elevated serum ferritin (>200 μg/L in females, >300 μg/L in males), according to the American Association for the Study of Liver Diseases 14
• The primary treatment for hereditary hemochromatosis is phlebotomy, as recommended by the medical community, and renal function should be monitored closely in patients taking deferasirox, especially in those with baseline renal impairment or concomitant nephrotoxic medications 14